Does CSF1 overexpression or rearrangement influence biological behaviour in tenosynovial giant cell tumours of the knee?
暂无分享,去创建一个
[1] H. Schreuder,et al. Severity classification of Tenosynovial Giant Cell Tumours on MR imaging. , 2018, Surgical oncology.
[2] J. Blay,et al. Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT). , 2018 .
[3] J. Blay,et al. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial. , 2018, The Lancet. Oncology.
[4] A. Italiano,et al. CSF-1R Inhibitor Development: Current Clinical Status , 2017, Current Oncology Reports.
[5] H. Schreuder,et al. Higher incidence rates than previously known in tenosynovial giant cell tumors , 2017, Acta orthopaedica.
[6] H. Gelderblom,et al. Limb Amputation after Multiple Treatments of Tenosynovial Giant Cell Tumour: Series of 4 Dutch Cases , 2017, Case reports in orthopedics.
[7] A. B. Hassan,et al. A phase I/II dose escalation and expansion study of cabiralizumab (cabira; FPA-008), an anti-CSF1R antibody, in tenosynovial giant cell tumor (TGCT, diffuse pigmented villonodular synovitis D-PVNS). , 2017 .
[8] S. Cannon,et al. Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre. , 2017, The Knee.
[9] M. Mulcahey,et al. Pigmented Villonodular Synovitis: A Comprehensive Review and Proposed Treatment Algorithm , 2016, JBJS reviews.
[10] J. Maher,et al. Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. , 2016, Biochemical Society transactions.
[11] P. Cassier,et al. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis , 2016, Current Treatment Options in Oncology.
[12] J. Blay,et al. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. , 2015, The Lancet. Oncology.
[13] M. van de Rijn,et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. , 2015, The New England journal of medicine.
[14] C. Antonescu,et al. Tenosynovial giant cell tumour/pigmented villonodular synovitis: outcome of 294 patients before the era of kinase inhibitors. , 2015, European journal of cancer.
[15] H. Schreuder,et al. Long-term follow-up results of primary and recurrent pigmented villonodular synovitis. , 2014, Rheumatology.
[16] M. A. van de Sande,et al. Functional outcome and quality of life after the surgical treatment for diffuse-type giant-cell tumour around the knee: a retrospective analysis of 30 patients. , 2014, The bone & joint journal.
[17] B. Bjerkehagen,et al. Novel CSF1-S100A10 fusion gene and CSF1 transcript identified by RNA sequencing in tenosynovial giant cell tumors , 2014, International journal of oncology.
[18] J. Hung,et al. Colony-stimulating factor 1 potentiates lung cancer bone metastasis , 2014, Laboratory Investigation.
[19] H. Gelderblom,et al. A multidisciplinary approach to giant cell tumors of tendon sheath and synovium—A critical appraisal of literature and treatment proposal , 2013, Journal of surgical oncology.
[20] C. Fletcher,et al. WHO classification of tumours of soft tissue and bone , 2013 .
[21] L. White,et al. Long‐term outcome of the treatment of high‐risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery , 2012, Cancer.
[22] J. Blay,et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis , 2012, Cancer.
[23] J. Flanagan,et al. RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. , 2012, The Journal of molecular diagnostics : JMD.
[24] R. West,et al. Translocation and Expression of CSF1 in Pigmented Villonodular Synovitis, Tenosynovial Giant Cell Tumor, Rheumatoid Arthritis and Other Reactive Synovitides , 2007, The American journal of surgical pathology.
[25] Robert J. Marinelli,et al. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[26] H. Tanke,et al. COBRA: combined binary ratio labeling of nucleic-acid probes for multi-color fluorescence in situ hybridization karyotyping , 2006, Nature Protocols.
[27] B. Bjerkehagen,et al. Molecular cytogenetic characterization of tenosynovial giant cell tumors. , 2004, Neoplasia.
[28] M. Belosevic,et al. Regulation of myeloid development and function by colony stimulating factors. , 2004, Developmental and comparative immunology.
[29] P. D. Dal Cin,et al. Molecular cytogenetic mapping of recurrent chromosomal breakpoints in tenosynovial giant cell tumors , 2002, Virchows Archiv.
[30] H. Tanke,et al. Simultaneous molecular karyotyping and mapping of viral DNA integration sites by 25‐color COBRA‐FISH , 2000, Genes, chromosomes & cancer.
[31] F. Mitelman,et al. Analysis of 35 cases of localized and diffuse tenosynovial giant cell tumor: a report from the Chromosomes and Morphology (CHAMP) study group. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[32] Y. Kaneko,et al. Short arm of chromosome 1 aberration recurrently found in pigmented villonodular synovitis. , 1996, Cancer genetics and cytogenetics.
[33] F. Mitelman,et al. Chromosome aberrations in tenosynovial giant cell tumors and nontumorous synovial tissue , 1993, Genes, chromosomes & cancer.
[34] J. Fletcher,et al. Trisomy 5 and trisomy 7 are nonrandom aberrations in pigmented villonodular synovitis: Confirmation of trisomy 7 in uncultured cells , 1992, Genes, chromosomes & cancer.
[35] M. Houman,et al. Tissue crosslinks concentrations in normal joints and chronic articular diseases , 1997, Annals of the rheumatic diseases.